Date: 2015-04-10
Type of information: Opening of new premises
Compound: manufacturing facility in Russia
Company: Novo Nordisk (Denmark)
Therapeutic area: Metabolic diseases
Type agreement: opening of new premises
Action mechanism:
Disease: diabetes
Details:
- • On April 10, 2015, Novo Nordisk announced the opening of a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes. The production will cover both Penfill® cartridges and FlexPen® prefilled insulin injection pens for the Russian market. The new facility will be operating in accordance with current Good Manufacturing Practices (GMP), and is located in Technopark Grabtsevo in the Kaluga region of Russia. This is the first and only greenfield facility for the manufacturing of modern insulin in Russia. Environmental targets for CO² emission, water consumption and use of energy have been established. With the construction of the new facility, Novo Nordisk has so far created around 150 new jobs. Novo Nordisk also has production sites in Denmark, Brazil, China, France and the US.
Financial terms:
Latest news:
Is general: Yes
